LPCN vs OSRH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LPCN exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.68 and negligible debt, these are offset by a catastrophic 67.2% year-over-year revenue collapse and an operating margin of -219.65%. The technical trend is entirely bearish (0/100), and the stock has lost over 90% of its value over five years. Despite a lone analyst's optimistic $11.00 target, the data suggests a company in operational distress.
OSRH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic Current Ratio of 0.16, indicating an inability to meet short-term obligations. The company is experiencing a collapse in top-line growth with revenue declining 58.30% YoY, coupled with an unsustainable operating margin of -1674.81%. While the Price-to-Book ratio of 0.19 suggests deep value, the lack of liquidity and negative earnings trajectory point toward a high risk of insolvency. The single analyst target of $10.00 is completely decoupled from the current fundamental reality.
Compare Another Pair
Related Comparisons
LPCN vs OSRH: Head-to-Head Comparison
This page compares Lipocine Inc. (LPCN) and OSR Holdings, Inc. (OSRH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.